Friday, February 20, 2026
Symposium Agenda
Jump To A Session
REGISTRATION // EXHIBITS // BREAKFAST
7:30 am-8:30 am
INDUSTRY PRODUCT THEATER
Evidence-Based Treatment for Recurrent Pericarditis
SPEAKER: Rigved Tadwalkar, MD | Providence St. Joseph Health
TIME: 7:45 am-8:15 am
LOCATION: Divisible Conference Room
Session 1: Cardiomyopathy—Genotypes, Phenotypes & Endotypes
-
Welcome Remarks
Event Co-Directors: Eric Adler, MD · Marcus Urey, MD · Kimberly Hong, MD · Quan Bui, MD
8:30 AM -
HCM: Updates in Clinical Therapies
Ahmad Masri, MD, MS
8: 45 AM -
Genetic Testing in 2025: How Does It Change Practice
Quan Bui, MD
9:00 AM -
Insights into Mechanisms of Dilated Cardiomyopathy
Zoltan P. Arany, MD, PhD
9:15 AM -
The True Guide to Precision Care: Genotype, Endotype, or Phenotype?
DISCUSSION PANEL
9:30 AM
Session 2: The Genetic Revolution Is Here, Or Is It?
-
Whole Genome Sequencing: The Future, or Always the Future?
Victoria Parikh, MD
10:00 AM -
Genetic Testing of Hyperlipidemia
Samuel Tsimikas, MD, FAHA, FACC, FSCAI
10:15 AM -
Treatment of LPA
Harpreet Bhatia, MD, MAS
10:30 AM -
Why Aren’t We Testing More Patients? Should We?
DISCUSSION PANEL
10:45 AM
Session 3: Unraveling ATTR—Pathophysiology, Imaging & Intervention
-
Transthyretin Amyloidosis Pathophysiology: Why Is There Destabilization and What Drives Organ Infiltration?
Marcus A. Urey, MD
11:30 AM -
Imaging for Diagnosis and Surveillance: Can We Rely on Novel Imaging Tools to Quantify Amyloid Burden?
Brett W. Sperry, MD
11:45 AM -
KEYNOTE: Disease Targeted Therapies: Can Early Diagnosis and Treatment Initiation Halt Disease Progression?
Ahmad Masri, MD, MS
12:00 PM -
Stabilizers, Silencers, or Antibodies - Which is First Line?
DISCUSSION PANEL
12:15 PM
LUNCH BREAK & POSTER PRESENTATIONS
12:45 pm-2:00 pm
INDUSTRY PRODUCT THEATER
An Extended Overview of Attruby for ATTR-CM
SPEAKER: Marcus A. Urey, MD | UC San Diego
TIME: 12:50 pm-1:50 pm
LOCATION: Divisible Conference Room
Session 4: Therapeutic Innovation & Value in Rare Disease
-
KEYNOTE: Economics of Innovation – Who’s Paying and Who’s Benefiting from Precision Cardiac Care?
Robert M. Califf, MD, MACC
2:00 PM -
Challenges In and Strategies to Improve Rare Disease Health Technology Assessments
Daniel A. Ollendorf, PhD
2:20 PM -
Valuation of Rare Disease Therapeutics Using Real-World Evidence
Michael Hogarth, MD, FACMI
2:35 PM -
Partnerships for Progress: Identifying Value Inflections
DISCUSSION PANEL
2:50 PM
Session 5: Frontiers in Genetic & Molecular Therapies
-
Overview of Ex Vivo Gene Therapy – Applications for Genetic Disorders
Stephanie Cherqui, PhD
3:30 PM -
Overview of Gene Therapies
Kimberly N. Hong, MD, MHSA
3:45 PM -
RNA: ASO, siRNA, and Gene Editing
Gene W. Yeo, PhD, MBA
4:00 PM -
RNA, DNA, or Protein: Where Should We Focus Our Investments?
INDUSTRY ROUNDTABLE
Moderator: Josh Schimmer, MD
4:15 PM
Session 6: Patients Are Waiting
-
Patient Perspectives: Targeting Cardiovascular Treatment
PATIENT PANEL
4:45 PM -
Closing Remarks
Eric D. Adler, MD, FACC
5:15 PM
POST-SYMPOSIUM MIXER
Details Coming
6:00 PM